Sequoia China invests in HiFiBiO Therapeutics
Client(s) Sequoia China
Jones Day represented Sequoia China in connection with its purchase of Series B Convertible Preferred Stock in a private placement by HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis.